Photo by nci from unsplash
Since 2007, for patients with advanced- or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for locoregional treatments and with preserved liver function, the multikinase inhibitor (MKI) sorafenib has been the worldwide standard… Click to show full abstract
Since 2007, for patients with advanced- or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for locoregional treatments and with preserved liver function, the multikinase inhibitor (MKI) sorafenib has been the worldwide standard of care [...].
Keywords:
hepatocellular carcinoma;
novel therapies;
carcinoma;
therapies hepatocellular
Journal Title: Cancers
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancers
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!